Influence of Histamine H1, H2, and H3 Agonists and Antagonists on IgE Mediated Histamine Release from Human Basophils

Kleine-Tebbe, J.; Schramm, Julian; Bolz, Marianne; Gagné, H.; C, Josties; Lipp, Ralph; Friese, Anika; Stark, Holger; Zingel, V.; Buschauer, Armin; Schunack, Walter; Kunkel, G.

doi:10.1007/978-3-642-46717-2_21

Cited by 2 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to salmeterol, the shorter acting β-2 agonist salbutamol was essentially ineffective at inhibiting the release of either mediator. This observation is in agreement to previous reports which showed that salbutamol and isoprenaline are only weakly active on basophils in terms of histamine release (Warner et al 1988;Kleine-Tebbe et al 1994).…”

Section: Discussionsupporting

confidence: 94%

“…Additionally, the drug has also been shown to inhibit histamine release from basophils and mast cells which accounts for the reduction in vascular permeability due to the amine in both the airways and the skin (Johnson et al 1993;Kleine-Tebbe et al 1994). We are able to not only confirm these observations with respect to histamine release but also show that salmeterol inhibits the release of both IL-4 and IL-13.…”

Section: Discussionsupporting

confidence: 68%

See 1 more Smart Citation

Inhibition of interleukin-4 and interleukin-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs

Gibbs

Vollrath

Albrecht

et al. 1998

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Human basophils have recently been shown to rapidly produce and release interleukin (IL-)4 and IL-13 as well as histamine and eicosanoids. Since both IL-4 and IL-13 can initiate and maintain late phase allergic reactions we addressed whether some widely used anti-allergic drugs can inhibit the anti-IgE induced release of these cytokines from enriched human basophils. Basophils were enriched (47-92% purity) by Ficoll density centrifugation followed by elutriation and negative selection of contaminating cells using immunomagnetic beads. Basophils were stimulated with sub-optimal dilutions of anti-IgE in the presence or absence of various drugs and the release of histamine and cytokines were measured after 30 min and 4 h, respectively. The beta-2 agonist salmeterol, the H1-receptor antagonist terfenadine and the phosphodiesterase inhibitor theophylline inhibited the release of IL-4 and IL-13 by more than 50% following 4 h of basophil stimulation with anti-IgE. These drugs also inhibited the release of histamine following 30 min stimulation, although with less efficacy than for IL-4 and IL-13. Short preincubation of basophils with salmeterol or terfenadine before stimulation gave rise to significantly greater inhibition of histamine release but had less effect on the inhibition of cytokine release. The effects of theophylline, however, were not significantly affected by preincubation of the cells with the drug. In contrast to the aforementioned drugs, salbutamol and cetirizine were ineffective at inhibiting both histamine and cytokine release from basophils. These results suggest that a number of anti-allergic drugs may mediate their effects, in part, in reducing late phase allergic responses due to their actions on IL-4 and IL-13 secretion from basophils.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 68%

Inhibition of interleukin-4 and interleukin-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs

Gibbs

Vollrath

Albrecht

et al. 1998

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

show abstract

“…É potente inibidor da ativação de mastócitos, inibe a liberação de histamina, leucotrienos (LT) C4, LTD4 e prostaglandina D2 de fragmento de pulmão humano 11 , diminue a liberação de LTB4 de neutrófilos humanos 12 , de tromboxane B2 liberado de macrófagos alveolares 13 e de histamina de basófilos humanos 14 . Além disso, é capaz de bloquear o aumento de permeabilidade da microciruclação induzida pelo fator ativador de plaquetas e pela histamina.…”

Section: Discussionunclassified

“…Considerando o salmeterol, este permitiu efeito broncodilatador duradouro e constitui medicação adequada, segundo o recomendado pelos vários consensos para manejo da asma, no tratamento da asma moderada/grave. [14][15][16][17][18][19]: asma aguda, b2 agonista, salmeterol, b2 agonista de longa duração.…”

Section: Introductionunclassified

Duration of bronchodilator effect of inhaled Salmeterol (dry powder x metered dose inhaler) in children with acute asthma attack

Solé¹,

Rizzo²,

Porto³

et al. 1996

J Pediatr (Rio J)

View full text Add to dashboard Cite

Patients during a mild to moderate acute attack of asthma (FEV1: 50 -80% of predicted) were treated with Salmeterol MDI -50mcg or Rotadisk -50mcg or Salbutamol (MDI200mcg). The children were followed by Spirometry, measuring FEV1 (basal) and after treatment: at 30 minutes, 60 minutes and thereafter every 60 minutes until 780 minutes, if the patients mantained the FEV1 above 80% of the predicted value and/or an increment of 20% in the VEF1 basal value. The Salmeterol group showed a significant bronchodilation at 60 minutes which was maintained in half of the patients up to 9 hours. This was not observed in the Salbutamol group: the peak bronchodilatation was observed at 30 minutes and the bronchodilation effect was observed in half of the patients up to 6 hours. There were no significant differences between both presentations of Salmeterol. This drug allowed a prolonged bronchodilator effect and is, according to the several consensus on management of asthma, an adequate option in the treatment of moderate to severe asthma.

show abstract

Influence of Histamine H1, H2, and H3 Agonists and Antagonists on IgE Mediated Histamine Release from Human Basophils

Cited by 2 publications

References 6 publications

Inhibition of interleukin-4 and interleukin-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs

Inhibition of interleukin-4 and interleukin-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs

Duration of bronchodilator effect of inhaled Salmeterol (dry powder x metered dose inhaler) in children with acute asthma attack

Contact Info

Product

Resources

About